BHGZD effectively improved disease severity of active RA rats, elevating pain thresholds, relieving joint inflammation and bone erosion via inhibiting TLR4/PI3K/AKT/NFκB signaling to suppress the activation of the NLRP3 inflammasome. This evidence concerns the gene NFKB1 and rheumatoid arthritis.